ICYMI: INZ-701 Begets Positive Data in Clinical Study on ABCC6 Deficiency and ENPP1 Deficiency
source: pixabay.com

ICYMI: INZ-701 Begets Positive Data in Clinical Study on ABCC6 Deficiency and ENPP1 Deficiency

Biopharmaceutical company Inozyme Pharma ("Inozyme") has become a leader at the forefront of developing innovative therapies for rare diseases such as ENPP1 deficiency (the childhood form is known as generalized…

Continue Reading ICYMI: INZ-701 Begets Positive Data in Clinical Study on ABCC6 Deficiency and ENPP1 Deficiency
Rare Community Profiles: Creating a Strong Patient Advocacy-Pharma Partnership: How Inozyme Pharma and GACI Global Came Together for Impact
Photo courtesy of GACI Global

Rare Community Profiles: Creating a Strong Patient Advocacy-Pharma Partnership: How Inozyme Pharma and GACI Global Came Together for Impact

  Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

Continue Reading Rare Community Profiles: Creating a Strong Patient Advocacy-Pharma Partnership: How Inozyme Pharma and GACI Global Came Together for Impact
Rare Community Profiles: Inozyme’s Catherine Nester Discusses Newborn Screening and the GACI Diagnostic Delay
Fotocitizen / Pixabay

Rare Community Profiles: Inozyme’s Catherine Nester Discusses Newborn Screening and the GACI Diagnostic Delay

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Inozyme’s Catherine Nester Discusses Newborn Screening and the GACI Diagnostic Delay
World Orphan Drug Congress USA 2023: Inozyme HCP and Patient Engagement Executive Discuss Importance of Technology and Partnerships in Rare Disease Diagnosis and Treatment
source: shutterstock.com

World Orphan Drug Congress USA 2023: Inozyme HCP and Patient Engagement Executive Discuss Importance of Technology and Partnerships in Rare Disease Diagnosis and Treatment

The World Orphan Drug Congress USA 2023 was held from May 23-25, 2023, at the Gaylord National Resort & Convention Center in National Harbor, MD. This conference is focused solely…

Continue Reading World Orphan Drug Congress USA 2023: Inozyme HCP and Patient Engagement Executive Discuss Importance of Technology and Partnerships in Rare Disease Diagnosis and Treatment
GACI/ARHR2 Awareness Day is February 1st: Spreading rare Disease Awareness
source: pixabay.com

GACI/ARHR2 Awareness Day is February 1st: Spreading rare Disease Awareness

Generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemia rickets type 2 (ARHR2) Awareness Day is recognized each year on Feb 1. This is a time for spreading awareness…

Continue Reading GACI/ARHR2 Awareness Day is February 1st: Spreading rare Disease Awareness

Investigative Treatment for ENPP1 Deficiency Has Moved to Phase 1/2 Clinical Trial

Inozyme Pharma has recently announced that the first patient was dosed in its Phase 1/2 clinical trial of INZ-701 in adult patients with ABCC6 Deficiency and the second cohort in…

Continue Reading Investigative Treatment for ENPP1 Deficiency Has Moved to Phase 1/2 Clinical Trial